Global Blood Therapeutics
Global Blood Therapeutics is a biotechnology company focused on developing an oral, small molecule drug, GTx011 that restores the normal hemoglobin dynamics for patients with sickle cell disease.
One of the earliest, rare genetic diseases to be defined on a molecular basis, sickle cell disease is caused by a single genetic mutation. This mutation alters the oxygen-transport protein hemoglobin and causes chronic pain, acute pain, organ damage, high risk of stroke and renal insufficiency. Deerfield invested through GBT’s $48 million Series B financing which will be used to advance GTx011 development.